Does the media favor EYPT or INVA?

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Innoviva. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 12 mentions for Innoviva. Innoviva's average media sentiment score of 1.69 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innoviva 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to LBRX or EYPT?

In the previous week, Eyepoint Pharmaceuticals had 7 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 6 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.17 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer EYPT or HROW?

In the previous week, Eyepoint Pharmaceuticals had 10 more articles in the media than Harrow. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 3 mentions for Harrow. Harrow's average media sentiment score of 1.42 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harrow 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EYPT or ANRO?

In the previous week, Eyepoint Pharmaceuticals had 8 more articles in the media than Alto Neuroscience. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 5 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.57 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Alto Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alto Neuroscience 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EYPT or CRON?

In the previous week, Eyepoint Pharmaceuticals had 9 more articles in the media than Cronos Group. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 4 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.82 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Eyepoint Pharmaceuticals (EYPT) Competitors

$4.57 -0.22 (-4.59%)

As of 09/3/2026 04:00 PM Eastern

Compare

EYPT vs. INVA, LBRX, HROW, ANRO, and CRON

Should you buy Eyepoint Pharmaceuticals stock or one of its competitors? Eyepoint Pharmaceuticals's main competitors and comparable companies include Innoviva (INVA), LB Pharmaceuticals (LBRX), Harrow (HROW), Alto Neuroscience (ANRO), and Cronos Group (CRON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eyepoint Pharmaceuticals compare to Innoviva?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Innoviva (NASDAQ:INVA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Eyepoint Pharmaceuticals presently has a consensus price target of $25.70, indicating a potential upside of 462.36%. Innoviva has a consensus price target of $34.75, indicating a potential upside of 62.76%. Given Eyepoint Pharmaceuticals' higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Innoviva	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Innoviva has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	12.56	-$231.96M	-$3.74	N/A
Innoviva	$411.33M	3.75	$271.17M	$4.10	5.21

Eyepoint Pharmaceuticals has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

Innoviva has a net margin of 81.19% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Innoviva's return on equity of 28.03% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Innoviva	81.19%	28.03%	20.19%

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Innoviva. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 12 mentions for Innoviva. Innoviva's average media sentiment score of 1.69 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	11 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Innoviva beats Eyepoint Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

LB Pharmaceuticals has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Eyepoint Pharmaceuticals	$31.37M	12.56	-$231.96M	-$3.74	N/A

LB Pharmaceuticals currently has a consensus price target of $49.63, indicating a potential upside of 4.43%. Eyepoint Pharmaceuticals has a consensus price target of $25.70, indicating a potential upside of 462.36%. Given Eyepoint Pharmaceuticals' higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

In the previous week, Eyepoint Pharmaceuticals had 7 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 6 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.17 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

LB Pharmaceuticals has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. LB Pharmaceuticals' return on equity of -25.92% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

Summary

LB Pharmaceuticals beats Eyepoint Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Harrow?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Harrow (NASDAQ:HROW) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Harrow has a net margin of -13.51% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Harrow's return on equity of -38.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Harrow	-13.51%	-38.00%	-3.37%

Harrow has higher revenue and earnings than Eyepoint Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	12.56	-$231.96M	-$3.74	N/A
Harrow	$272.30M	5.27	-$5.14M	-$1.00	N/A

Eyepoint Pharmaceuticals presently has a consensus price target of $25.70, suggesting a potential upside of 462.36%. Harrow has a consensus price target of $69.43, suggesting a potential upside of 81.47%. Given Eyepoint Pharmaceuticals' higher probable upside, research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Harrow	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Eyepoint Pharmaceuticals had 10 more articles in the media than Harrow. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 3 mentions for Harrow. Harrow's average media sentiment score of 1.42 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harrow	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Harrow has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Summary

Harrow beats Eyepoint Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Alto Neuroscience (NYSE:ANRO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Alto Neuroscience has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Alto Neuroscience's return on equity of -46.46% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Alto Neuroscience	N/A	-46.46%	-39.09%

Alto Neuroscience has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Alto Neuroscience is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	12.56	-$231.96M	-$3.74	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Eyepoint Pharmaceuticals has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

In the previous week, Eyepoint Pharmaceuticals had 8 more articles in the media than Alto Neuroscience. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 5 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.57 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Alto Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alto Neuroscience	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals currently has a consensus target price of $25.70, suggesting a potential upside of 462.36%. Alto Neuroscience has a consensus target price of $37.25, suggesting a potential upside of 2.99%. Given Eyepoint Pharmaceuticals' higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Alto Neuroscience beats Eyepoint Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Cronos Group?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Eyepoint Pharmaceuticals presently has a consensus price target of $25.70, suggesting a potential upside of 462.36%. Cronos Group has a consensus price target of $2.30, suggesting a potential downside of 29.45%. Given Eyepoint Pharmaceuticals' higher possible upside, equities analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Cronos Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Eyepoint Pharmaceuticals had 9 more articles in the media than Cronos Group. MarketBeat recorded 13 mentions for Eyepoint Pharmaceuticals and 4 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.82 beat Eyepoint Pharmaceuticals' score of -0.14 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cronos Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 7.8% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Eyepoint Pharmaceuticals has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Cronos Group has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Cronos Group has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	12.56	-$231.96M	-$3.74	N/A
Cronos Group	$146.59M	8.20	-$9.45M	$0.20	16.30

Cronos Group has a net margin of 39.08% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Cronos Group's return on equity of 4.85% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Cronos Group	39.08%	4.85%	4.62%

Summary

Cronos Group beats Eyepoint Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Eyepoint Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EYPT vs. The Competition

Export

Metric	Eyepoint Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$412.96M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-1.22	787.27	273.29	25.38
Price / Sales	12.56	753.79	613.45	92.55
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	2.37	12.33	12.89	6.14
Net Income	-$231.96M	$2.82B	$3.47B	$349.01M
7 Day Performance	2.01%	2.59%	0.60%	-0.27%
1 Month Performance	-60.84%	6.95%	5.73%	0.68%
1 Year Performance	-61.53%	9.45%	25.35%	14.84%

Eyepoint Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EYPT Eyepoint Pharmaceuticals	2.499 of 5 stars	$4.57 -4.6%	$25.70 +462.4%	-61.9%	$412.96M	$31.37M	N/A	120	Analyst Upgrade
INVA Innoviva	3.2696 of 5 stars	$21.08 +1.5%	$34.75 +64.9%	+2.2%	$1.52B	$411.33M	5.14	100	Positive News
LBRX LB Pharmaceuticals	1.2254 of 5 stars	$47.04 -0.5%	$49.63 +5.5%	N/A	$1.52B	N/A	N/A	16	News Coverage
HROW Harrow	2.9543 of 5 stars	$37.08 +0.5%	$69.43 +87.2%	+2.5%	$1.39B	$272.30M	N/A	180	Positive News
ANRO Alto Neuroscience	1.1704 of 5 stars	$34.76 -1.7%	$37.25 +7.2%	+900.6%	$1.36B	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EYPT) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. INVA, LBRX, HROW, ANRO, and CRON

How does Eyepoint Pharmaceuticals compare to Innoviva?

Summary

How does Eyepoint Pharmaceuticals compare to LB Pharmaceuticals?

Summary

How does Eyepoint Pharmaceuticals compare to Harrow?

Summary

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Summary

How does Eyepoint Pharmaceuticals compare to Cronos Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. INVA, LBRX, HROW, ANRO, and CRON

How does Eyepoint Pharmaceuticals compare to Innoviva?

Do institutionals & insiders hold more shares of EYPT or INVA?

Do analysts prefer EYPT or INVA?

Which has higher earnings & valuation, EYPT or INVA?

Which has more volatility and risk, EYPT or INVA?

Is EYPT or INVA more profitable?

Does the media favor EYPT or INVA?

Summary

How does Eyepoint Pharmaceuticals compare to LB Pharmaceuticals?

Which has better earnings & valuation, LBRX or EYPT?

Do analysts prefer LBRX or EYPT?

Does the media refer more to LBRX or EYPT?

Do insiders & institutionals have more ownership in LBRX or EYPT?

Is LBRX or EYPT more profitable?

Summary

How does Eyepoint Pharmaceuticals compare to Harrow?

Is EYPT or HROW more profitable?

Which has stronger valuation & earnings, EYPT or HROW?

Do analysts rate EYPT or HROW?

Do institutionals & insiders hold more shares of EYPT or HROW?

Does the media prefer EYPT or HROW?

Which has more volatility & risk, EYPT or HROW?

Summary

How does Eyepoint Pharmaceuticals compare to Alto Neuroscience?

Do institutionals and insiders hold more shares of EYPT or ANRO?

Is EYPT or ANRO more profitable?

Which has better earnings and valuation, EYPT or ANRO?

Which has more volatility and risk, EYPT or ANRO?

Does the media prefer EYPT or ANRO?

Do analysts recommend EYPT or ANRO?

Summary

How does Eyepoint Pharmaceuticals compare to Cronos Group?

Do analysts recommend EYPT or CRON?

Does the media prefer EYPT or CRON?

Do insiders and institutionals hold more shares of EYPT or CRON?

Which has more risk & volatility, EYPT or CRON?

Which has preferable valuation and earnings, EYPT or CRON?

Is EYPT or CRON more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools